Breast Cancer Research

Table 2 Summary of combined results of the genome-wide association study and additional genotyped data

From: A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients

						ADR^c				Non-ADR^d				Pvalue
SNP	CHR	Chromosome position^a	Gene	Allele 1/2 (risk)		11	12	22	RAF	11	12	22	RAF	Allelic	Dominant	Recessive	Pmin	OR^b(95% CI)
rs3820706	2	152957411	CACNB4	A/G	GWAS	18	169	116	0.66	167	421	291	0.57	8.26E-05	1.07E-01	8.13E-09	8.13E-09	3.71
rs3820706	2	152957411	CACNB4	A/G	GWAS	18	169	116	0.66	167	421	291	0.57	8.26E-05	1.07E-01	8.13E-09	8.13E-09	(2.24-6.15)
				(G)	2nd	1	12	10	0.70	167	421	291	0.57	9.80E-02	3.70E-01	1.00E-01	9.80E-02	1.72
				(G)	2nd	1	12	10	0.70	167	421	291	0.57	9.80E-02	3.70E-01	1.00E-01	9.80E-02	(0.91-3.25)
					Combine	19	181	126	0.66	167	421	291	0.57	3.16E-05	7.65E-02	1.85E-09	1.85E-09	2.38
					Combine	19	181	126	0.66	167	421	291	0.57	3.16E-05	7.65E-02	1.85E-09	1.85E-09	(1.44-3.93)
rs16830728	2	152981335	STAM2	G/T	GWAS	17	163	123	0.68	153	422	304	0.59	1.11E-04	6.16E-02	7.24E-08	7.24E-08	3.54
rs16830728	2	152981335	STAM2	G/T	GWAS	17	163	123	0.68	153	422	304	0.59	1.11E-04	6.16E-02	7.24E-08	7.24E-08	(2.11-5.96)
				(T)	2nd	1	11	11	0.72	153	422	304	0.59	9.40E-02	1.91E-01	1.55E-01	9.40E-02	1.79
				(T)	2nd	1	11	11	0.72	153	422	304	0.59	9.40E-02	1.91E-01	1.55E-01	9.40E-02	(0.94-3.43)
					Combine	18	174	134	0.68	153	422	304	0.59	3.49E-05	4.30E-02	2.60E-08	2.60E-08	3.61
					Combine	18	174	134	0.68	153	422	304	0.59	3.49E-05	4.30E-02	2.60E-08	2.60E-08	(2.17-5.98)
rs7476422	10	56204291	PCDH15	T/G	GWAS	4	47	252	0.91	34	245	601	0.82	1.20E-07	3.77E-07	3.58E-02	1.20E-07	2.17
rs7476422	10	56204291	PCDH15	T/G	GWAS	4	47	252	0.91	34	245	601	0.82	1.20E-07	3.77E-07	3.58E-02	1.20E-07	(1.60-2.93)
				(G)	2nd	0	7	16	0.85	34	245	601	0.82	8.45E-01	1.00E+00	1.00E+00	8.45E-01	1.21
				(G)	2nd	0	7	16	0.85	34	245	601	0.82	8.45E-01	1.00E+00	1.00E+00	8.45E-01	(0.53-2.72)
					Combine	4	54	268	0.91	34	245	601	0.82	2.63E-07	1.15E-06	2.41E-02	2.63E-07	2.06
																		(1.54-2.75)

^aOn the basis of NCBI 36 genome assembly; ^bORs and CIs are calculated according to the associated genetic model; ^cindividuals who developed grade 2 alopecia; ^dindividuals who did not developed any ADRs after chemotherapy. The same controls were used in the GWAS and second stages analysis. SNP, single nucleotide polymorphism; CHR, chromosome; ADR, adverse drug reaction; RAF, risk allele frequency; P min, minimum P value; OR, odds ratio; CI, confidence interval.

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com